RxDoctor Payments Data

Scott Rutkoski

Optometrist · Wellsboro, PANPI 1750392775

Payments from drug & device makers

$1,065in general payments, 2019–2025

Across 48 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$316
  • Alcon$250
  • Astellas Pharma US Inc$147
  • LKC Technologies, Inc.$102
  • Sun Pharmaceutical Industries Inc.$68
  • Novartis$68
  • plus $114 from 5 others

What the payments were for

  • Food & beverage$1,065100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,065 in reported general payments places this provider in the 55th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$458,551
Medicare patients
1,616
Services billed
6,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost552$276,174
RestasisCyclosporine71$87,987
XiidraLifitegrast52$65,312
RhopressaNetarsudil Mesylate114$51,944
Cyclosporine68$39,072
VyzultaLatanoprostene Bunod68$35,371
SimbrinzaBrinzolamide/Brimonidine Tart107$32,141
RocklatanNetarsudil Mesylat/Latanoprost65$29,489
TyrvayaVarenicline Tartrate24$16,616
Alphagan PBrimonidine Tartrate33$14,199
Travoprost64$14,111
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol60$12,848
CombiganBrimonidine Tartrate/Timolol28$11,845
Brinzolamide37$8,625
Brimonidine Tartrate201$8,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$30$100,683120 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$13$81,434179 claims
AlconSimbrinza$250$32,141107 claims
Oyster Point Pharma, Inc.Tyrvaya$316$16,61624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Wellsboro

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →